453 related articles for article (PubMed ID: 24389297)
1. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
Poddubnyy D; Hermann KG; Callhoff J; Listing J; Sieper J
Ann Rheum Dis; 2014 May; 73(5):817-23. PubMed ID: 24389297
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
[TBL] [Abstract][Full Text] [Related]
4. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
5. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.
Song IH; Heldmann F; Rudwaleit M; Haibel H; Weiss A; Braun J; Sieper J
Ann Rheum Dis; 2011 Jun; 70(6):1108-10. PubMed ID: 21415053
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
7. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial.
Haibel H; Brandt HC; Song IH; Brandt A; Listing J; Rudwaleit M; Sieper J
Ann Rheum Dis; 2007 Mar; 66(3):419-21. PubMed ID: 16901959
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of intravenous methylprednisolone in the treatment of patients with active ankylosing spondylitis: results of a 12-week, prospective, open-label, pilot (METALL) study].
Gaydukova IZ; Rebrov AP; Poddubnyi DA
Ter Arkh; 2015; 87(5):47-52. PubMed ID: 26155618
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
[TBL] [Abstract][Full Text] [Related]
11. Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial.
Li Q; Li L; Bi L; Xiao C; Lin Z; Cao S; Liao Z; Gu J
Trials; 2016 Jul; 17(1):337. PubMed ID: 27449221
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
[TBL] [Abstract][Full Text] [Related]
15. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
Machado P; Landewé RB; Braun J; Baraliakos X; Hermann KG; Hsu B; Baker D; van der Heijde D
Ann Rheum Dis; 2012 Dec; 71(12):2002-5. PubMed ID: 22915615
[TBL] [Abstract][Full Text] [Related]
16. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
[TBL] [Abstract][Full Text] [Related]
17. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
Marzo-Ortega H; Sieper J; Kivitz AJ; Blanco R; Cohen M; Pavelka K; Delicha EM; Stefanska A; Richards HB; Rohrer S
Lancet Rheumatol; 2020 Jun; 2(6):e339-e346. PubMed ID: 38273597
[TBL] [Abstract][Full Text] [Related]
18. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
Sieper J; van der Heijde D; Dougados M; Brown LS; Lavie F; Pangan AL
Ann Rheum Dis; 2012 May; 71(5):700-6. PubMed ID: 22128084
[TBL] [Abstract][Full Text] [Related]
19. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
van der Heijde D; Braun J; Dougados M; Sieper J; Pedersen R; Szumski A; Koenig AS
Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
